These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 3883503)

  • 1. Megestrol acetate v tamoxifen in advanced breast cancer: a phase III trial of the Piedmont Oncology Association (POA).
    Muss HB; Paschold EH; Black WR; Cooper MR; Capizzi RL; Christian R; Cruz JM; Jackson DV; Stuart JJ; Richards F
    Semin Oncol; 1985 Mar; 12(1 Suppl 1):55-61. PubMed ID: 3883503
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Megestrol acetate versus tamoxifen in advanced breast cancer: 5-year analysis--a phase III trial of the Piedmont Oncology Association.
    Muss HB; Wells HB; Paschold EH; Black WR; Cooper MR; Capizzi RL; Christian R; Cruz JM; Jackson DV; Powell BL
    J Clin Oncol; 1988 Jul; 6(7):1098-106. PubMed ID: 3292710
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Megestrol acetate v tamoxifen in advanced breast cancer in postmenopausal patients.
    Morgan LR
    Semin Oncol; 1985 Mar; 12(1 Suppl 1):43-7. PubMed ID: 3975652
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase III trial comparing anastrozole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with megestrol acetate in postmenopausal women with advanced breast carcinoma. Arimidex Study Group.
    Buzdar AU; Jones SE; Vogel CL; Wolter J; Plourde P; Webster A
    Cancer; 1997 Feb; 79(4):730-9. PubMed ID: 9024711
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fadrozole HCL (CGS-16949A) versus megestrol acetate treatment of postmenopausal patients with metastatic breast carcinoma: results of two randomized double blind controlled multiinstitutional trials.
    Buzdar AU; Smith R; Vogel C; Bonomi P; Keller AM; Favis G; Mulagha M; Cooper J
    Cancer; 1996 Jun; 77(12):2503-13. PubMed ID: 8640699
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study Group.
    Buzdar AU; Jonat W; Howell A; Jones SE; Blomqvist CP; Vogel CL; Eiermann W; Wolter JM; Steinberg M; Webster A; Lee D
    Cancer; 1998 Sep; 83(6):1142-52. PubMed ID: 9740079
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized trial of megestrol acetate with or without premarin in the treatment of potentially responsive metastatic breast cancer. A Study of the Eastern Cooperative Oncology Group (E2185).
    Cobau CD; Declercq K; Neuberg D; Ingle JN; Tormey DC
    Cancer; 1996 Feb; 77(3):483-9. PubMed ID: 8630955
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Megestrol acetate v tamoxifen in advanced breast cancer: correlation of hormone receptors and response.
    Ettinger DS; Allegra J; Bertino JR; Bonomi P; Browder H; Byrne P; Carpenter J; Catalano R; Creech R; Dana B
    Semin Oncol; 1986 Dec; 13(4 Suppl 4):9-14. PubMed ID: 3026052
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic use of tamoxifen in advanced breast cancer: correlation with biochemical parameters.
    Morgan LR; Schein PS; Woolley PV; Hoth D; Macdonald J; Lippman M; Posey LE; Beazley RW
    Cancer Treat Rep; 1976 Oct; 60(10):1437-43. PubMed ID: 191185
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of antiestrogen and progestogen therapy for initial treatment and consequences of their combination for second-line treatment of recurrent breast cancer.
    Paterson AH; Hanson J; Pritchard KI; Sansregret E; Dahrouge S; McDermot RS; Fine S; White DF; Trudeau M; Stewart DJ
    Semin Oncol; 1990 Dec; 17(6 Suppl 9):52-62. PubMed ID: 2259927
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Weight changes in women with metastatic breast cancer treated with megestrol acetate: a comparison of standard versus high-dose therapy.
    Cruz JM; Muss HB; Brockschmidt JK; Evans GW
    Semin Oncol; 1990 Dec; 17(6 Suppl 9):63-7. PubMed ID: 2259928
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-dose megestrol acetate therapy of ovarian carcinoma: a phase II study by the Northern California Oncology Group.
    Sikic BI; Scudder SA; Ballon SC; Soriero OM; Christman JE; Suey L; Ehsan MN; Brandt AE; Evans TL
    Semin Oncol; 1986 Dec; 13(4 Suppl 4):26-32. PubMed ID: 3099393
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Megestrol acetate in the treatment of advanced post-menopausal breast cancer.
    Benghiat A; Cassidy SA; Davidson HE; Mancero FS; Pickard JG; Tyrrell CJ
    Eur J Surg Oncol; 1986 Mar; 12(1):43-5. PubMed ID: 3956753
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Primary hormonal therapy of advanced breast cancer with megestrol acetate: predictive value of estrogen receptor and progesterone receptor levels.
    Bonomi P; Johnson P; Anderson K; Wolter J; Bunting N; Strauss A; Roseman D; Shorey W; Economou S
    Semin Oncol; 1985 Mar; 12(1 Suppl 1):48-54. PubMed ID: 3975653
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Investigations on the nutritional status of advanced breast cancer patients. The influence of long-term treatment with megestrol acetate or tamoxifen.
    Schrijver J; Alexieva-Figusch J; van Breederode N; van Gilse HA
    Nutr Cancer; 1987; 10(4):231-45. PubMed ID: 3432093
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemotherapy plus sequential hormonal therapy for advanced and recurrent endometrial carcinoma: a phase II study.
    Pinelli DM; Fiorica JV; Roberts WS; Hoffman MS; Nicosia SV; Cavanagh D
    Gynecol Oncol; 1996 Mar; 60(3):462-7. PubMed ID: 8774658
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantitative estrogen and progesterone receptor levels related to progression-free interval in advanced breast cancer patients treated with megestrol acetate or tamoxifen.
    Bonomi P; Gale M; Von Roenn J; Anderson K; Johnson P; Wolter J; Economou S
    Semin Oncol; 1988 Apr; 15(2 Suppl 1):26-33. PubMed ID: 3368797
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral versus im administration of high-dose medroxyprogesterone acetate in pretreated patients with advanced breast cancer.
    Beex L; Burghouts J; van Turnhout J; Breed W; Hillen H; Holdrinet A; Boetius G; Hoogendoorn G; Doesburg W; Verhulst M
    Cancer Treat Rep; 1987 Dec; 71(12):1151-6. PubMed ID: 3690524
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Are all aromatase inhibitors the same? A review of controlled clinical trials in breast cancer.
    Berry J
    Clin Ther; 2005 Nov; 27(11):1671-84. PubMed ID: 16368441
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical results with megestrol acetate in patients with advanced carcinoma of the breast.
    Ansfield FJ; Kallas GJ; Singson JP
    Surg Gynecol Obstet; 1982 Dec; 155(6):888-90. PubMed ID: 7147170
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.